TABLE 7.
Ongoing Androgen Deprivation Therapy Plus Chemotherapy Trials
| Study | Phase | Estimated Primary Completion |
|---|---|---|
| Docetaxel Before Degarelix in Newly Diagnosed Metastatic Prostate Cancer (NCT03069937) | 2 | February 2020 |
| PEACE1 (A Phase III Study for Patients with Metastatic Hormone-Naïve Prostate Cancer; NCT01957436) | 3 | 2020 |
| S1216 (ADT + TAK-700 vs ADT + Bicalutamide for Metastatic Prostate Cancer; NCT01809691) | 3 | March 2022 |
| ARASENS (ODM-201/Darolutamide in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer; NCT02799602) | 3 | August 2022 |
| STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy; NCT00268476) | 2/3 | September 2024 |
| Arm A (control: ADT + radiotherapy ± docetaxel ± abiraterone) | ||
| Arm C (ADT + docetaxel + prednisolone) | ||
| Arm E (ADT + zoledronic acid + docetaxel + prednisolone) | ||
| Arm G (ADT + abiraterone + prednisolone) | ||
| Arm J (ADT + abiraterone + enzalutamide + prednisolone) |